Lupin Limited has informed the Exchange regarding a press release dated January 09, 2023, titled "Lupin and Exeltis Announce Reimbursement Approval of NaMuscla�� in Spain for theSymptomatic Treatment of Myotonia in Adults with non-dystrophic myotonic (NDM)Disorders.".